Patent classifications
A61L31/043
PEPTIDE THERAPIES FOR REDUCTION OF MACULAR THICKENING
Compounds comprising R-G-Cysteic Acid (i.e., R-G-NHCH(CH.sub.2SO.sub.3H)COOH or Arg-Gly-NHCH(CH.sub.2SO.sub.3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to .sub.5.sub.1-Integrin, .sub.v.sub.3-Integrin and .sub.v.sub.5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
Implantable meshes for controlling the movement of fluids
Meshes for use to control the movement of bodily fluids, such as blood, are described herein. The mesh can be partially or completely biodegradable or non-biodegradable. In one embodiment, the mesh is formed from one or more self-assembling peptides. The peptides can be in the form of fibers, such as nanofibers. The peptides can be assembled prior to formation of the mesh or after the mesh has been formed but before it is applied. Alternatively, the mesh can be prepared from unassembled peptides, which assemble at the time of application. The peptides can assemble upon contact with bodily fluids (e.g., blood) or can be contacted with an ionic solution to initiate assembly.
ORTHODONTIC ADHESIVES AND METHODS OF USING SAME
An orthodontic adhesive includes components capable of allowing easy debonding of an orthodontic device from a patient's tooth. The adhesive includes an engineered marine mussel protein. The adhesive may include at least one photocleavable moiety. The adhesive is applied in one or more individual layers. One of the components of the adhesive is capable of binding to a tooth and the other component may be capable of binding to an orthodontic device. A method of adhering an orthodontic device to a tooth includes applying a layer of an orthodontic adhesive to either the tooth or the orthodontic device or the tooth and the orthodontic device and affixing the orthodontic device to the tooth with the orthodontic adhesive situated between the tooth and the orthodontic device. The engineered marine mussel protein includes one or more catechol moieties or one or more derivatives of a catechol moiety.
Systems, devices and methods for the creation of a therapeutic restriction in the gastrointestinal tract
A system for treating a patient comprises a delivery device and injectate. The delivery device comprises an elongate shaft with a distal portion and at least one delivery element positioned on the elongate shaft distal portion. The delivery device is constructed and arranged to deliver the injectate through the at least one delivery element and into tissue to create a therapeutic restriction in the gastrointestinal tract. Methods of creating a therapeutic restriction are also provided.
Implantable urological device with improved retrieval feature
A urological medical device having a retrieval string is provided. The retrieval string has a proximal end connected the device and an opposed distal end. In a first embodiment, the retrieval string is configured in an initial confined form which, following a period of deployment in a patient's bladder, changes to an unconfined form in which the distal end of the retrieval string is extendible into the urethra to enable extraction of the device from bladder by pulling the retrieval string. The device may include a bioerodible component which permits the retrieval string to take the unconfined form following degradation of the bioerodible component in vivo. In another embodiment, the retrieval string includes a ferromagnetic material, which can be magnetically captured to facilitate removal of the device from the bladder. The ferromagnetic retrieval string may be buoyant in urine.
Graft material having heated puncture structure and method
A needle lattice is used to form openings within a graft material to selectively enhance permeability of a prosthesis for tissue integration therein. The needle lattice may be disposed on, for example, a surface of a roller or press. The needle lattice precisely places openings in any pattern and location, and on any textile that forms the graft material. The needle lattice can be heated to fuse the surrounding material of the openings of the textile to prevent movement of the textiles and to prevent collapse of the openings. All parameters of the openings, including varying density, patterns, and size of each opening, can be controlled, allowing for the opportunity to selectively enhance and optimize the permeability of the graft material in a vessel. The needle lattice can quickly form multiple openings within a graft material, allowing for quick manufacturing of the prosthesis.
MEDICAL APPARATUS AND ADHESION PROMOTING DEVICE USING SAME
To reduce the risk of a ruptured suture after a surgery or the like, a medical apparatus includes a biodegradable sheet in which a plurality of through-holes are formed, a value of a ratio (D/P) of a hole diameter D to a pitch P of the through-hole is in a range of 0.25 or more and less than 40. Such a medical apparatus is useful as an adhesion promoting device for promoting adhesion of biological tissue.
COMPOSITIONS AND METHODS FOR INHIBITING CELLULAR ADHESION OR DIRECTING DIAGNOSTIC OR THERAPEUTIC AGENTS TO RGD BINDING SITES
Compounds comprising R-G-Cysteic Acid (i.e., R-G-NHCH(CH.sub.2SO.sub.3H)COOH or Arg-Gly-NHCH(CH.sub.2SO.sub.3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
Quenched coating
Described is an object surface coating comprising one or more polymers and a peptide covalently linked to at least one of said one or more polymers, said peptide comprising a) a first cleavage site, wherein said first cleavage site is cleaved by a first compound specifically provided by a microbe belonging to a first group consisting of a limited number of microbial strains, species or genera, and not cleaved by any compound provided by any microbe not belonging to said first group, b) a first fluorescent agent having an emission wavelength of 650-900 nm, c) a first non-fluorescent agent having an absorption wavelength of 650-900 nm, for quenching said emission of said first fluorescent agent, wherein cleavage of said first cleavage site results in the release of said first non-fluorescent agent from the coating, the release of said first non-fluorescent agent being indicative for the presence of a microbe belonging to said first group.
Quenched coating
Described is an object surface coating comprising one or more polymers and a peptide covalently linked to at least one of said one or more polymers, said peptide comprising a) a first cleavage site, wherein said first cleavage site is cleaved by a first compound specifically provided by a microbe belonging to a first group consisting of a limited number of microbial strains, species or genera, and not cleaved by any compound provided by any microbe not belonging to said first group, b) a first fluorescent agent having an emission wavelength of 650-900 nm, c) a first non-fluorescent agent having an absorption wavelength of 650-900 nm, for quenching said emission of said first fluorescent agent, wherein cleavage of said first cleavage site results in the release of said first non-fluorescent agent from the coating, the release of said first non-fluorescent agent being indicative for the presence of a microbe belonging to said first group.